Ainos (AIMD) Competitors $0.51 -0.01 (-1.88%) As of 03/28/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AIMD vs. OVID, PLUR, INKT, SNYR, MRNS, COEP, VRCA, ELEV, GDTC, and UBXShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Ovid Therapeutics (OVID), Pluri (PLUR), MiNK Therapeutics (INKT), Synergy CHC Corp. (Uplisting) (SNYR), Marinus Pharmaceuticals (MRNS), Coeptis Therapeutics (COEP), Verrica Pharmaceuticals (VRCA), Elevation Oncology (ELEV), CytoMed Therapeutics (GDTC), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Ovid Therapeutics Pluri MiNK Therapeutics Synergy CHC Corp. (Uplisting) Marinus Pharmaceuticals Coeptis Therapeutics Verrica Pharmaceuticals Elevation Oncology CytoMed Therapeutics Unity Biotechnology Ainos (NASDAQ:AIMD) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, community ranking, valuation, earnings, analyst recommendations and media sentiment. Do insiders & institutionals have more ownership in AIMD or OVID? 72.2% of Ovid Therapeutics shares are held by institutional investors. 10.4% of Ainos shares are held by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer AIMD or OVID? Ovid Therapeutics has a consensus price target of $3.03, indicating a potential upside of 766.67%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ovid Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is AIMD or OVID more profitable? Ainos has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Ainos' return on equity.Company Net Margins Return on Equity Return on Assets AinosN/A -75.16% -50.22% Ovid Therapeutics -5,142.56%-39.24%-26.19% Does the media favor AIMD or OVID? In the previous week, Ovid Therapeutics had 10 more articles in the media than Ainos. MarketBeat recorded 13 mentions for Ovid Therapeutics and 3 mentions for Ainos. Ovid Therapeutics' average media sentiment score of 0.62 beat Ainos' score of 0.46 indicating that Ovid Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ainos 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, AIMD or OVID? Ainos has higher earnings, but lower revenue than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAinos$20.73K379.85-$13.77M-$1.65-0.31Ovid Therapeutics$566K43.95-$52.34M-$0.38-0.92 Does the MarketBeat Community favor AIMD or OVID? Ovid Therapeutics received 357 more outperform votes than Ainos when rated by MarketBeat users. CompanyUnderperformOutperformAinosN/AN/AOvid TherapeuticsOutperform Votes35770.97% Underperform Votes14629.03% Which has more volatility & risk, AIMD or OVID? Ainos has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. SummaryOvid Therapeutics beats Ainos on 13 of the 18 factors compared between the two stocks. Remove Ads Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.87M$6.90B$5.63B$7.84BDividend YieldN/A2.78%5.33%4.01%P/E Ratio-0.317.2623.6018.74Price / Sales379.85218.66388.2490.77Price / CashN/A65.6738.1734.64Price / Book0.106.386.894.23Net Income-$13.77M$142.34M$3.20B$247.47M7 Day Performance-3.74%-5.15%-3.06%-2.29%1 Month Performance-4.37%-7.55%1.52%-5.81%1 Year Performance-55.25%-11.06%9.37%-0.96% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos0.4766 of 5 stars$0.51-1.9%N/A-55.2%$7.87M$20,729.00-0.3140Short Interest ↑Gap DownOVIDOvid Therapeutics4.4474 of 5 stars$0.46-1.3%$3.20+595.7%-88.5%$32.69M$566,000.00-0.9860Analyst RevisionPLURPluri1.0092 of 5 stars$4.65-1.6%N/A-31.9%$32.50M$678,000.00-0.83150Short Interest ↓INKTMiNK Therapeutics2.228 of 5 stars$8.09-5.0%$37.50+363.5%-0.6%$32.06MN/A-2.0730SNYRSynergy CHC Corp. (Uplisting)3.7091 of 5 stars$3.54-1.1%$10.00+182.5%N/A$30.81M$26.01M0.0040Positive NewsMRNSMarinus Pharmaceuticals2.3208 of 5 stars$0.55-0.2%$4.79+771.6%-93.9%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageCOEPCoeptis Therapeutics0.7886 of 5 stars$9.27+9.0%N/A+57.7%$30.04MN/A-1.602Positive NewsGap UpVRCAVerrica Pharmaceuticals4.2316 of 5 stars$0.65-0.5%$9.50+1,368.3%-92.7%$29.50M$7.57M-0.3540ELEVElevation Oncology2.6387 of 5 stars$0.49-6.8%$6.83+1,294.6%-94.9%$29.02MN/A-0.6040GDTCCytoMed Therapeutics2.4657 of 5 stars$2.65+6.9%$5.00+88.7%+3.2%$28.99MN/A0.00N/AShort Interest ↓Positive NewsUBXUnity Biotechnology4.1123 of 5 stars$1.71-2.6%$7.33+330.1%-30.5%$28.76M$240,000.00-1.3060Analyst ForecastAnalyst Revision Remove Ads Related Companies and Tools Related Companies OVID Competitors PLUR Competitors INKT Competitors SNYR Competitors MRNS Competitors COEP Competitors VRCA Competitors ELEV Competitors GDTC Competitors UBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AIMD) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
